Jazz Pharmaceuticals officer proposes $473K sale
The proposed shares are identified as restricted stock acquired from Jazz Pharmaceuticals on June 30, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jazz Pharmaceuticals plc reports that Officer Renee D. Gala proposes to sell 2,000 common shares on October 6, 2026, through Morgan Stanley Smith Barney LLC. The proposed sale has an aggregate market value of $472,800.00 and is listed for NASDAQ. The shares are identified as restricted stock acquired from the issuer on June 30, 2026. The notice also lists a sale of 2,000 common shares on September 8, 2026, with an aggregate market value of $486,060.00.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock financial
aggregate market value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.